|[February 20, 2013]
Research and Markets: Baxter International 2013 Company Report
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/c27564/baxter)
has announced the addition of the "Baxter
International Medical Device Company Intelligence Report"
report to their offering.
Baxter International Inc develops, manufactures and markets products for
the treatment of haemophilia, immune disorders, infectious diseases,
kidney disease, trauma and other chronic and acute medical conditions.
The company applies a combination of expertise in medical devices,
pharmaceuticals and biotechnology.
Prior to 2011, Baxter operated under three business segments:
BioScience, Medication Delivery and Renal. As of 1st January 2011, the
company combined its Medication Delivery and Renal businesses into a
single global business unit to form the Medical Products business.
In December of 2012, Baxter entered into a definitive agreement to
acquire privately-held Gambro, for total consideration approximately
US$4.0 billion. Gambro is a global medical technology company focused on
developing, manufacturing and supplying dialysis products and therapies
for patients with acute or chronic kidney disease. The acquisition will
give Baxter a comprehensive dialysis product portfolio, complementing
its existing home dialysis offerings.
It is believed that the transaction will provide a number of long-term
growth opportunities for Baxter worldwide. With a broad and
complementary dialysis product portfolio, Baxter can accelerate product
sales in established markets such as Europe, where Gambro has an
extensive footprint. Baxter can also expand Gambro's reach in
high-growth regions of Latin America and Asia-Pacific, where Baxter has
steadily grown its peritoneal dialysis business. In addition, Baxter
will also build upon its pipeline of investigational home haemodialysis
and automated PD systems with the addition of Gambro's monitors,
dialysers, devices and dialysis systems.
In January 2012, Baxter rejected an unsolicited mini-tender offer by TRC
Capital Corporation to purchase up to two million shares, or
approximately 0.35%, of Baxter's outstanding common stock at a price of
US$46.10 per share in cash. The offer price was 4.67% below the US$48.36
closing price of Baxter's common stock on 15th December 2011, the day
prior to the offer.
In Business Monitor International's list of top ten US medical device
manufacturers 2006-2011, Baxter was ranked in fourth position, behind
Johnson & Johnson, GE and Medtronic. This profile primarily concentrates
on Baxter's medical device activities.
Key Topics Covered
- Key contact information
- Introduction to the company and its current activities
- Summary of its financial performance
- Who are the company's major competitors
- Key recent events in an at a glance format
- Current year and annual financial data, including revenue breakdowns
by product area and geographic region (if available)
- Table providing in-depth five-year financial analysis
- Employee data, including breakdown by company division and geographic
Investigates the company's aims and its areas of focus
Core product areas, key brands, product approvals and launches
Research and Development
- How much has been invested in R&D
- Where is the research based
- What alliances and agreements does the company have and with whom
Manufacturing and Distribution
- Identifying the company's manufacturing locations
- Sales and marketing facilities
- With whom has the company reached agreements and what do they involve
- Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Key Corporate Events
For more information visit http://www.researchandmarkets.com/research/c27564/baxter
[ Back To Technology News's Homepage ]